title: High levels of oestrogen receptor-alpha in tumorigenesis: inhibition of cell growth and angiogenic factors.
abstract: We previously found that the stable overexpression of oestrogen receptor-alpha in the human endothelial cell line ECV304* inhibits its growth in vitro, and that this inhibition is possibly mediated through a down-regulation of the vasoactive agents endothelin-1 and vascular endothelial growth factor. Here we show an in vivo growth-inhibitory effect of oestrogen receptor-alpha overexpression in tumours initiated in nude mice from the same clone of ECV304. In addition, we show that this growth inhibition is accompanied by an alphavbeta3-mediated inhibition of cell migration in vitro, and a down-regulation of the integrin alphavbeta3, vascular endothelial growth factor and vascularization in vivo. The levels of vascular endothelial growth factor and integrin alphavbeta3, through their effect on cell growth and migration, contribute to the process of angiogenesis and to the pathogenesis of atherosclerosis and cancer. The results shown here demonstrate that a higher level of oestrogen receptor-alpha in the cell, through its effect on certain angiogenic factors, may play a role in the control of angiogenesis.
authors.affiliation: Diabetes-Endocrinology Center of Western New York, Kaleida Health System, Buffalo, NY, USA. syedhali@hotmail.com
authors.forename: S H
authors.initials: SH
authors.lastname: Ali
authors.forename: A L
authors.initials: AL
authors.lastname: O'Donnell
authors.forename: D
authors.initials: D
authors.lastname: Balu
authors.forename: M B
authors.initials: MB
authors.lastname: Pohl
authors.forename: M J
authors.initials: MJ
authors.lastname: Seyler
authors.forename: S
authors.initials: S
authors.lastname: Mohamed
authors.forename: S
authors.initials: S
authors.lastname: Mousa
authors.forename: P
authors.initials: P
authors.lastname: Dandona
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D002461:Cell Line, Transformed; D002465:Cell Movement / Q000187:drug effects; D002999:Clone Cells; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D016228:Endothelial Growth Factors / Q000378:metabolism / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D047628:Estrogen Receptor alpha; D005260:Female; D015870:Gene Expression / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008222:Lymphokines / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009383:Neoplasms, Vascular Tissue / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000503:physiopathology; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism*; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors / Q000378:metabolism; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: C426703:3-(3-(3-(4,5-dihydroimidazol-2-ylamino)propyloxylisoxazol-5-yl)carbonylamino)-2-(phenylsulfonylamino)propionic acid; D000906:Antibodies; D016228:Endothelial Growth Factors; D047628:Estrogen Receptor alpha; D007093:Imidazoles; D008222:Lymphokines; D011960:Receptors, Estrogen; D019030:Receptors, Vitronectin; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D004958:Estradiol